Navigation Links
Tengion Announces Significant Advances in Neo-Urinary Conduit™ and Neo-Kidney Augment™ Programs
Date:3/26/2012

ll complete implantation of up to 10 patients by the end of 2012.

Neo-Kidney Augment Preclinical Program Update
Tengion submitted a pre-IND filing to the FDA for its lead preclinical program, the Neo-Kidney Augment, one quarter ahead of schedule. The Neo-Kidney Augment is intended to prevent or delay the need for dialysis or kidney transplant by catalyzing the regeneration of functional kidney tissue in patients with advanced chronic kidney disease (CKD). Following the early submission of the pre-IND, Tengion's Board of Directors has authorized the Company to aggressively pursue the development of its Neo-Kidney Augment program and will retain the full team of employees involved in the Neo-Kidney Augment program.

Tengion has scheduled a meeting with the FDA to discuss the Company's proposed GLP animal study program to support an IND filing. Tengion is also exploring moving forward using the Advanced Therapy Medicinal Products (ATMP) pathway, an established regulatory route in Europe for advanced cell-based therapies. The Company expects to provide an update on its expectations for the clinical trial program in its first quarter 2012 financial results announcement in May.

About the Neo-Urinary Conduit
The Neo-Urinary Conduit is a combination of a patient's own cells and bioabsorbable scaffold that is intended to catalyze regeneration of a native bladder tissue conduit, passively transporting urine from the ureters through a stoma, or hole in the abdomen, into a standard ostomy bag. Standard of care for patients requiring a non-continent urinary diversion uses bowel tissue to construct a conduit for urine to exit from the body. There are over 20,000 urinary diversions performed annually in the United States and Europe. These patients are at risk for complications associated with the use of bowel tissue, as well as for those associated with the surgery to harvest the bowel tissue. The Neo-Urinary Conduit is the only product c
'/>"/>

SOURCE Tengion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Tengion Appoints John L. Miclot President and Chief Executive Officer
2. Tengion to Present at Piper Jaffray 23rd Annual Health Care Conference
3. Tengion Provides Business Update and Reports Third Quarter 2011 Financial Results
4. Tengion Appoints Scott Flora to Board of Directors
5. Tengion Appoints Diane Jorkasky, M.D., to its Board of Directors
6. Tengion Provides Update on Neo-Urinary Conduit Clinical Trial
7. Tengion Announces FDA Orphan-Drug Designation for Neo-Urinary Conduit
8. Tengion Presents New Data in Nine Posters and Two Oral Presentations at TERMIS North America Annual Meeting
9. Tengion Advances Clinical Trial for Neo-Urinary Conduit™ in Bladder Cancer Patients
10. Tengion Provides Business Update and Reports Third Quarter 2010 Financial Results
11. Tengion Reviews Pipeline Progress at First Analyst and Investor Meeting; Strategic & Clinical Updates Provided for Regenerative Medicine Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015 /PRNewswire/ - Medicure Inc. (the ... Directors has approved the grant of an aggregate of ... employees and consultants of the Company pursuant to the ... set to expire on the tenth anniversary of the ... the third anniversary of the date of grant and ...
(Date:3/27/2015)... , March 27, 2015 /CNW Telbec/ - ... Research-Based Pharmaceutical Companies (Rx&D), welcomes the 2015-2016 Quebec ... a working group on the biopharmaceutical industry. However, the ... budget. "We commend the government,s intent to ... announcement of measures to promote Quebec,s ...
(Date:3/27/2015)... Biopharmaceutical Industry Leads Manufacturing Sector in R&D Spending ... as the country,s manufacturing leader in innovation and economic ... to the  analysis , the industry had the highest ... accounting for 27 percent of average annual R&D spending ... on Medicare Part D - Medicare Part D ...
Breaking Medicine Technology:Quebec 2015-2016 Budget: Rx&D welcomes fiscal discipline and biopharma working group, but the decrease in government spending on medicines is questioned 2Quebec 2015-2016 Budget: Rx&D welcomes fiscal discipline and biopharma working group, but the decrease in government spending on medicines is questioned 3Week in Review: The Latest from PhRMA 2
... 28 Amira Pharmaceuticals, Inc. announced today that it ... a novel LPA1 antagonist, in normal, healthy subjects. ... exploring the therapeutic value of AM152, a potentially novel ... safety, pharmacodynamic (PD) and pharmacokinetic (PK) profile of this ...
... Millennium Research Group (MRG), the global authority ... latest orthopedics research data including information for multiple ... extremity devices. MRG orthopedic biomaterial reports ... and material, hyaluronic acid viscosupplementation treatments by number ...
Cached Medicine Technology:Amira Pharmaceuticals Announces Initiation of Phase I Clinical Trial for AM152, A Novel LPA1 Antagonist 2New Orthopedic Market Research Data Covering Multiple Geographies Released by Millennium Research Group 2
(Date:3/28/2015)... Pitching speed, player’s height, and pitching for ... elbow injuries, according to new research released today at the ... Day. , “Our findings indicate that a 10 inch increase ... of a history of injury, a 10 mile per hour ... of a history of injury, and playing for more than ...
(Date:3/28/2015)... Vegas, NV (PRWEB) March 28, 2015 ... injuries is a growing field in orthopaedic medicine. While ... labral tear to confirm the pain etiology, research presented ... ( AOSSM ) Specialty Day suggests that pain relief ... following arthroscopic hip surgery. , “Our study looked ...
(Date:3/28/2015)... Las Vegas, NV (PRWEB) March 28, 2015 ... option for patients with Type V AC joint injuries, ... The study, presented today at the American Orthopaedic Society ... military personnel returned to duty faster when surgery was ... 24 patients, with 7 receiving surgical treatment and 17 ...
(Date:3/28/2015)... March 28, 2015 Andrew Hawley of Vintage ... Who psychedelic concert posters. The Who and the Doors played ... August 2, 1968. According to Hawley, “The Who toured the ... halls and college campuses. Perhaps the most famous Who poster ... Morrison and the Doors on August 2, 1968 at the ...
(Date:3/28/2015)... Omaha, NE (PRWEB) March 28, 2015 ... leader in healthcare staffing, including physical therapy jobs, ... exhibitor at the Ohio Physical Therapy Association Annual ... the Renaissance Columbus Downtown Hotel in Columbus, OH. ... programming, networking opportunities, and exhibits with products and ...
Breaking Medicine News(10 mins):Health News:Researchers Highlight Shoulder and Elbow Injury Possibility in Youth Players 2Health News:Pain Injections for Hip Arthroscopy Patients May Not Predict Surgical Outcomes 2Health News:For Type V AC Joint Injuries, Early Surgery May Not Be the Best Approach 2Health News:Avid Collector from Vintage Rock Posters, Inc. Announces His Search For Original 1960's Who Psychedelic Concert Posters. 2Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the Ohio Physical Therapy Association Annual Conference 2
... , ... "Company") (Nasdaq: CMED ), a leading China-based,medical device company ... its unaudited financial results,for the second fiscal quarter ended September ... on March 31, 2010 ("FY2009"). , , ...
... , PORTLAND, Ore., Nov. 18 Despite ... a wide variety of charities as part of the ... approximately 50 percent match, communities in Regence,s four-state region ... to serving those in need is an important cornerstone ...
... Nov. 18 GettingHired, LLC , an ... announced today that it has secured $3 million of additional ... employment portal in the USA as well as final development ... initiative supporting the long term disability and workers, compensation insurance ...
... , , NORTH HOLLYWOOD, Calif., ... ) announced today that it has acquired Hospital Internists of ... Internists of Westerly (HIW), based in Westerly, Rhode Island. The ... additional states, raising the company,s presence to 21 states. The ...
... may be continuous, infection state unclear , WEDNESDAY, Nov. 18 ... genital lesions, never truly goes into a dormant state, new ... it,s not causing an outbreak, the virus is shedding tiny ... study did not specifically address whether or not the very ...
... Plavix bested by latest anti-clotting alternatives , WEDNESDAY, Nov. ... three new trials suggest that the latest generation of ... clopidogrel (Plavix). , In one study, dabigatran etexilate (marketed ... is not yet approved in the United States) proved ...
Cached Medicine News:Health News:China Medical Technologies Reports Second Fiscal Quarter Financial Results 2Health News:China Medical Technologies Reports Second Fiscal Quarter Financial Results 3Health News:China Medical Technologies Reports Second Fiscal Quarter Financial Results 4Health News:China Medical Technologies Reports Second Fiscal Quarter Financial Results 5Health News:China Medical Technologies Reports Second Fiscal Quarter Financial Results 6Health News:China Medical Technologies Reports Second Fiscal Quarter Financial Results 7Health News:China Medical Technologies Reports Second Fiscal Quarter Financial Results 8Health News:China Medical Technologies Reports Second Fiscal Quarter Financial Results 9Health News:China Medical Technologies Reports Second Fiscal Quarter Financial Results 10Health News:China Medical Technologies Reports Second Fiscal Quarter Financial Results 11Health News:China Medical Technologies Reports Second Fiscal Quarter Financial Results 12Health News:China Medical Technologies Reports Second Fiscal Quarter Financial Results 13Health News:China Medical Technologies Reports Second Fiscal Quarter Financial Results 14Health News:Regence Employees Give Nearly $1.3 Million to Charity in Two-Week Period 2Health News:GettingHired Announces Additional Funding for Continued Growth as Well as R&D of New Product for Long Term Disability and Workers' Comp. 2Health News:GettingHired Announces Additional Funding for Continued Growth as Well as R&D of New Product for Long Term Disability and Workers' Comp. 3Health News:IPC The Hospitalist Company Acquires Two New England Practices 2Health News:Genital Herpes May Never Go Dormant 2Health News:Genital Herpes May Never Go Dormant 3Health News:Newer Blood Thinners May Outperform Old Standbys 2Health News:Newer Blood Thinners May Outperform Old Standbys 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: